Every 8-K that China Pharma (CPHI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CPHI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPHI filings page.
China Pharma Holdings, Inc. agreed on July 22, 2026 to sell 2,500,000 shares of common stock in a registered direct offering to an institutional accredited investor at $2.00 per share, for aggregate gross proceeds of $5,000,000, with closing expected on or around July 23, 2026.
The investor receives a right to participate in up to 40% of subsequent financings for three months after closing, while the company agrees for 91 days not to enter into subsequent placements or variable rate transactions, subject to exceptions. FT Global Capital, Inc. acts as exclusive placement agent and will receive a 7.0% cash commission on proceeds, plus a similar commission on qualifying financings with its contacted investors for 18 months after the placement agency agreement ends. The company plans to use net proceeds for working capital and general corporate purposes under an effective shelf registration statement (File No. 333-276481).
China Pharma Holdings, Inc. reported that its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd entered into a Technology Transfer Agreement on February 26, 2026 with Xiaoyan Zhang. The company will acquire an invention patent for Prinsepia Utilis Esterol sublingual tablets and related preparation methods.
As consideration, China Pharma agreed to pay $6.93 million in the form of its common stock at $0.55 per share, resulting in the planned issuance of 12,600,000 restricted shares of common stock. These shares will be issued to a non-U.S. person in an offshore transaction under Regulation S, and will not be registered under the U.S. Securities Act.
China Pharma Holdings, Inc. reported that its wholly owned subsidiary Hainan Helpson Medical & Biotechnology entered a Technology Transfer Agreement to acquire ownership of an invention patent for a Topiroxostat nanoemulsion and its preparation method from Xiaoyun Chen.
The transfer price is $8.82 million, to be paid in Company common stock at $0.70 per share, implying issuance of 12,600,000 restricted shares. Closing is expected by February 20, 2026. The shares will be issued in an offshore transaction to a non-U.S. person under Regulation S, without registration under the Securities Act.
China Pharma Holdings, Inc. reported results from its annual stockholders’ meeting for the fiscal year ended December 31, 2024. A total of 3,501,046 common shares, representing about 69.71% of outstanding shares as of the November 3, 2025 record date, were present in person or by proxy, providing a sufficient quorum.
Stockholders elected three independent directors—Gene Michael Bennett, Yingwen Zhang, and Baowen Dong—each receiving 3,500,416 to 3,500,418 votes for, with 628 to 630 votes withheld. Stockholders also approved an amendment to the Articles of Incorporation authorizing a reverse stock split at a ratio of up to 1-for-20 for the Company’s $0.001 par value common stock, with the Board retaining discretion over if and when to implement it. In addition, Amendment No. 3 to the Company’s Amended and Restated 2010 Long-Term Incentive Plan was approved, with 3,500,258 votes for, 774 against, and 14 abstentions.
China Pharma Holdings, Inc. reports that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement with Juan Zhang to acquire an invention patent covering Ipragliflozin tablets and their preparation method. The agreed transfer price is $9.8 million, to be paid in the company’s common stock at $1.40 per share.
To satisfy this consideration, the company is to issue 7,000,000 restricted shares of common stock. These shares will be offered and issued to a non-U.S. person in an offshore transaction relying on Regulation S, meaning they will not be registered under the U.S. Securities Act or state securities laws.
China Pharma Holdings, Inc. reports that its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, has entered into a Technology Transfer Agreement to acquire an invention patent for a Captopril microcapsule and its preparation method from an individual transferor. As consideration, the company values the transaction at $6.3 million, to be paid in shares of its common stock at $1.80 per share. In total, the company plans to issue 3,500,000 restricted common shares in connection with this technology transfer. The shares, if and when issued, will be offered in an offshore transaction to a non-U.S. person and will rely on Regulation S for exemption from registration under U.S. securities laws.